Revenue Recognition and Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue Recognition and Collaborative Arrangements
Net revenue	$ 90,059	$ 85,518
GSK | Royalty revenue from a related party
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	93,515	88,974
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)
Net revenue	90,059	85,518
GSK | RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	55,764	56,390
GSK | ANORO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	8,442	10,500
GSK | TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	$ 29,309	$ 22,084